EBF1 and Alzheimer disease: We found abnormalities in the B-cell receptor signaling pathway by conducting bioinformatics analysis in patients with MCI who will progress to AD in the future and identified EBF1 as a potential biomarker for predicting progression from MCI to AD through machine learning algorithms and others.